Medicine & TechnologyA comprehensive study on meningitis showed how the condition is induced by a fungal infection. Read more about how meningitis is initiated by deadly microbes.
Research showed that people over 65 years of age are at higher risk of experiencing breakthrough COVID-19. Know more about the virus’s link with Mental Health.
Scientists developed decoy nanoparticles, a new potential treatment for COVID-19. Learn about this new strategy in terms of efficacy in combating the virus.
Many people experience post-COVID-19 fatigue. Discover the difference between fatigue and tiredness after the infection and find out how alarming it can be.
A new study showed that the Omicron variant is less severe in children aged four years old and below compared to the Delta variant. Learn more about it here.
People with tuberculosis may not be infected with COVID-19 at the same time, a new study in mice suggested. Find out more about the new discovery here.
People all over the world are getting their booster shots for extra protection against COVID-19. Many now wonder if a 4th dose will be helpful. Find out what experts say about additional jabs and who is supposed to receive them.
Some outbreaks of the Ebola virus in Africa have been associated with persistent infection in patients who had survived past outbreaks, senior author of a recently published paper Xiankun "Kevin" Zeng said.
Some studies have recently suggested that up to 50 percent of all people who have overcome infection experience symptoms of long COVID, which include chest pains, tiredness, difficulty breathing, loss of taste or smell, and sore joints.
A new study recently described a new approach for "pyroptosis" analysis that's long believed to be lasting and once commenced, can certainly be paused and controlled.
Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
A new study finding recently showed that as much as 90 percent of tuberculosis bacteria released from an infected individual may be carried in droplets also known as aerosols that are expelled when one breathes out deeply.